Galcanezumab - Uses, Dosage, Side Effects, and More

Overview

Galcanezumab is used for treating the acute attacks of migraine in patients who are aged 18 and older. A specific characteristic of Galcanezumab is that it is an antagonist of calcitonin-gene-related peptide. Galcanezumab received approval from the Food and Drug Administration (FDA) on the 4th of June 2019, specifically for treating cluster headaches. Prior to this, Galcanezumab had already received the Food and Drug Administration approval for preventive treatment of migraine in adult patients on the 27th of September 2018.

What Are the Strengths and Dosage of Galcanezumab?

• Galcanezumab has been established to be a sterile and transparent liquid that is colorless and opalescent with a slight tinge of yellow or brown.

Mentioned below are the strengths and dosage forms of Galcanezumab. All the available forms are only for subcutaneous injection.

• 120 mg per mL as a prefilled single-dose pen.

• 120 mg per mL as a prefilled single-dose syringe

• 100 mg per mL as a prefilled single-dose syringe.

For Patients:

What Is Galcanezumab?

Galcanezumab is a medicine useful to treat people with migraine headaches and cluster headaches. Migraine actually refers to sudden episodes of throbbing headaches that may get severe over time and may also be accompanied by sensitivity to light, sound, and vomiting tendencies. Caffeine and chocolate are two of the most common trigger factors of migraine-type headaches. Cluster headaches refer to on-and-off episodes of headaches on any side of the head or only around one of the eyes. Galcanezumab blocks the normal functioning of certain chemicals and hormones of the body that are known to result in migraine headaches and cluster headaches.

What Are the Precautions That Must Be Taken Into Consideration Regarding Galcanezumab?

There are quite a few precautions that are supposed to be taken by the patient who is undergoing therapy with Galcanezumab. Hypersensitivity reaction is one of the most common conditions, generally seen immediately, after a week, or even after several days of administration of Galcanezumab. A hypersensitivity reaction can be understood as the presence of rash, difficulty breathing, and urticaria. The patient is advised to immediately discontinue the administration of Galcanezumab if any hypersensitivity reactions manifest.

How Is Galcanezumab Administered?

Galcanezumab is a subcutaneous injection self-administered by the patient or the caregiver. The accurate and exact manner of administration of the injection will be explained in great detail by the respective healthcare provider. The drug is available in single-shot pens or syringes. Particular drug administration sites are available, such as the buttocks, thigh, and abdomen, and their healthcare providers usually use the upper arm, but the preferred locations of drug administration are determined after performing a test dose for any hypersensitivity reactions.

What Are the Contraindications of Galcanezumab?

The subcutaneous administration of Galcanezumab injection is contraindicated in patients who are known to be hypersensitive to drugs or have a known hypersensitivity reaction with Galcanezumab-glnm in particular.

What Are the Adverse Reactions of Galcanezumab?

One of the most common adverse reactions to Galcanezumab is a hypersensitivity reaction, which results in clinical manifestations such as skin irritation, urticaria, redness, and swelling.

How Is Galcanezumab Stored?

Galcanezumab must be refrigerated and stored within a temperature range of 36 degrees Fahrenheit to 46 degrees Fahrenheit or two degrees Celsius to eight degrees Celsius. Galcanezumab must not be stored under direct sunlight and should be strictly kept from sunlight and other heat sources. The drug should not be frozen, nor should it be shaken before administration. Galcanezumab must be kept at room temperature for approximately 30 minutes before the subcutaneous injection. The drug must not be stored outside the suggested temperature ranges for more than seven days. Once the pill is unsealed, it must not be held again and thus must be used all at once. The puncture-resistant container must be discarded even if a single dose is contaminated, as mentioned in earlier instructions. In case the color of the drug is changed to gray or any other color other than those noted above, the drug is no longer fit to be subcutaneously administered and thus must be immediately discarded.

What Are the Benefits of Galcanezumab?

Specifically for migraine prevention, scientists produced the monoclonal antibody known as Galcanezumab. Its main benefit involves reducing migraine episode frequency because it works for people with both episodic and chronic migraines. Galcanezumab demonstrates superior safety performance compared to regular migraine treatments since it creates fewer adverse effects on patients. The drug stands as an appropriate candidate for extended use because of its positive properties.

For Doctors:

What Do You Treat With Galcanezumab?

Galcanezumab is indicated for the preventive treatment of migraine. Galcanezumab is also indicated for use in patients with cluster headache episodes.

Subcutaneous injection of Galcanezumab works as an antagonist to calcitonin-gene and peptides that are related to calcitonin-gene.

Galcanezumab-gnlm is an IgG4 monoclonal humanized antibody that is specific for CGRP or calcitonin-gene-related peptides ligand. Galcanezumab is produced and developed in CHO cells, known as Chinese Hamster Ovary, with the help of recombinant DNA technology. Galcanezumab comprises two immunoglobulin kappa light chains that are identical to each other. In addition to this, there are two immunoglobulin gamma heavy chains that are identical to each other. The overall molecular weight is around 147 kilodaltons.

What Are the Pharmacological Aspects of Galcanezumab?

Mechanism of Action: Galcanezumab is a monoclonal antibody that is humanized, and it binds to the CGRP ligand, also known as the calcitonin-gene-related peptide ligand. Galcanezumab also blocks the calcitonin-gene-related peptide ligand binding to its receptor site.

Pharmacodynamics: There has not been any deeper investigation into the pharmacodynamics of Galcanezumab, and thus, there is no relevant data about the pharmacodynamic alterations caused by Galcanezumab.

Pharmacokinetics: Galcanezumab displays a linear pattern of pharmacokinetics, and the exposure to the drug is directly proportional to the dose that has been administered. The loading dose after the first dose of Galcanezumab is 240 mg, which is achieved along with the steady state of serum Galcanezumab. It should be noted that, in the several studies and trials done with Galcanezumab, there had not been any discrepancy or dissimilarity in the pharmacokinetics of Galcanezumab between healthy subjects and subjects who were ill or had been suffering from chronic migraine and cluster headaches.

• Absorption: It takes approximately five days for Galcanezumab to attain the maximum concentration. The subcutaneous injection of Galcanezumab at any chosen administration site did not alter the rate of absorption.

• Distribution: The V/F, known as the apparent volume of distribution of the Galcanezumab, is 34 % IIV, or 34, and inter-individual variability equals 7.3 L.

• Elimination and Metabolism: Galcanezumab is expected to be degraded into minute peptides and small amino acids through a catabolic route, similar to the pathway followed by endogenous IgG. The CL/F, or apparent clearance, of Galcanezumab is 0.008 L/h. The half-life for its elimination is around 27 days.

What Are the Clinical Study and Trial Experiences With Galcanezumab?

• Approximately 2586 patients who have been suffering from migraine were evaluated for the safety and efficiency of Galcanezumab. Out of these patients, 1920 were directly exposed to Galcanezumab for a span of six months with the administration of a single dose per month. The remaining patients were under therapy with Galcanezumab for twelve months, with a single dose administration of the drug every month.

• Throughout the study, the strength of the medicine was 120 mg of Galcanezumab every month. The study was a double-blind treatment trial. 85 % of the candidates were female, and 77 % were Caucasian, with an average age of 41 years.

• Hypersensitivity reaction was observed to be one of the most common adverse reactions of Galcanezumab in patients suffering from migraine. In addition, pain and discomfort at the site of injection, itch, rash, erythema, and swelling were some signs and symptoms of the adverse reactions to Galcanezumab.

• Around 106 patients had been evaluated for the safety and efficiency of Galcanezumab in patients suffering from cluster headache episodes. Forty-nine of these patients were exposed to Galcanezumab, and the rest were on a placebo. The ones who were treated with Galcanezumab consisted of 88 % Caucasian patients with an average age of 47 years. The study was conducted in a double-blind manner.

• The strength of Galcanezumab in the trials done in patients suffering from cluster headache episodes was 300 mg administered monthly.

How Effective Is Galcanezumab?

According to clinical research, Galcanezumab is quite successful at lowering the number of migraine days that patients encounter. After beginning therapy, several study participants reported a considerable reduction in the frequency and intensity of their migraine attacks. The drug functions by preventing the calcitonin gene-related peptide (CGRP), a protein implicated in migraine development, from acting. Galcanezumab, therefore, not only aids in migraine prevention but also helps people who are afflicted have a more stable and controllable condition, which enhances their general satisfaction with migraine treatment.

What Are the Drug Interactions?

P450 enzyme is one of the cytochrome enzymes that does not metabolize Galcanezumab. Therefore, the interaction between Galcanezumab and P450 enzyme and concomitant drugs that may be inducers, substrates, or even cytochrome P450 enzyme inhibitors does not occur.

What Are the Nonclinical Toxicology Factors of Galcanezumab?

There has not been any carcinogenic or mutagenic study to understand the potential of Galcanezumab under the same aspects. The fertility of lab rats was not hampered due to the injection of Galcanezumab. The strength of Galcanezumab administered to the lab rats was approximately eight times more than the suggested dosage for human beings. Even before mating, subcutaneous administration of Galcanezumab in male and female lab rats did not lead to any abnormality in the pharmacokinetics of Galcanezumab.

What Are the Contraindications of Galcanezumab?

• Patients who are known to be allergic to Galcanezumab or similar drugs, or even the different components of the drug, are not allowed to go ahead with therapy with Galcanezumab.

• Instead, patients are advised to discuss with their respective healthcare providers whether they are pregnant or planning to get pregnant, whether they are lactating, suffering from any underlying medical condition, have a known hypersensitivity to any particular drug, or are allergic to specific groups of medicines.

What Are the Side Effects of Galcanezumab?

Hypersensitivity and allergic reactions are two of the most common side effects of Galcanezumab. Mentioned below are several side effects of the subcutaneous administration of Galcanezumab.

• Skin redness.

• Hives.

• Rashes.

• Irritations at the site of injection.

• Swelling.

• Difficulty in breathing.

• Sore throat.

• Inflammation of the tongue and the face.

• Bumps in the oral mucosa.

• Pain at the injection site.

• Blisters.

• Heat boils.

Specific Population:

• Pregnancy: There has not been a sufficient number of studies on pregnant patients who are supposed to undergo therapy with Galcanezumab. Thus, the amount of established results and shards of evidence about a pregnant patient undergoing Galcanezumab treatment is not sufficient to deliver a strong safety and efficiency summary. However, it should be noted that a good amount of established results prove an increased risk in pregnant patients for developing preeclampsia. There had been no adverse effects on the embryonic and fetal development of lab rats who were put under Galcanezumab therapy. There had not been any prenatal or postnatal alterations in lab rats.

• Lactation: There has not been enough research done on patients who are lactating. Animal tests and trials that were done on lactating lab rats did not find any specific presence of Galcanezumab in the milk. It should be noted that the high potency of drugs to be excreted in human milk, as well as no clinical trial having been done and no human milk tested for the presence of Galcanezumab, should lead to solid questioning and a need for the drug in patients who are lactating.

• Hepatic Impairment and Renal Impairment: Patients who are known to be suffering from impairment of the renal system or the hepatic system of the body will not show any alterations in the pharmacokinetics of Galcanezumab. Therefore, the creatinine clearance of patients suffering from renal and hepatic abnormalities may not lead to any kind of pharmacokinetic changes due to Galcanezumab. It should be noted that there has not been a deep study into the pharmacokinetic changes in patients suffering from hepatic and renal impairments.

Key Takeaway From iCliniq:

Galcanezumab is a migraine-preventive medication that works well to lessen the frequency and intensity of episodes. Its specific activity against calcitonin gene-related peptide (CGRP) improves patients' quality of life by providing a dependable choice with a good safety record. iCliniq has a team of highly professional doctors who are dedicated to guiding people with their knowledge and wisdom. Here at iCliniq, we can help you with all the information needed for the drug Galcanezumab, so you don't have to worry about your migraines anymore.